Abiopharma

🔍 Cicala Peter (Director)

Company: Ernexa Therapeutics Inc. (ERNA)

Report Date: 2026-08-31

Detailed Transactions and Holdings:

• Acquired 5,943 shares of Stock Option (Right to buy) at $4.57 per share (Derivative)
  Date: 2026-08-31 | Code: A | Expires: 2036-08-31 | equity_swap_involved: 0 | shares_owned_after: 5,943.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 5,083 shares of Stock Option (Right to buy) at $4.57 per share (Derivative)
  Date: 2026-08-31 | Code: A | Expires: 2036-08-31 | equity_swap_involved: 0 | shares_owned_after: 5,083.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.
• F2: Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.